Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apatinib + pemetrexed
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Apatinib + pemetrexed is a combination therapy used primarily in the treatment of advanced non-small cell lung cancer (NSCLC), especially after failure of prior lines of chemotherapy. Apatinib is an orally bioavailable small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting tumor angiogenesis[3][5]. Pemetrexed is a folate analog antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication and is approved for use in NSCLC and malignant pleural mesothelioma[7]. The combination has shown synergistic antitumor effects by enhancing antiangiogenic activity and delaying resistance to antiangiogenic therapy[2][5]. Clinical studies have demonstrated promising efficacy and manageable safety profiles for this regimen in heavily pretreated NSCLC patients[1][5].
- Brand names
- AlimtaAiTan
- Other names
- apatinib mesylate
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)GART (GAR transformylase)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on Apatinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apatinib + pemetrexed.